menu
    • menu
    [{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0.35999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.35999999999999999,"dosageForm":"Capsule","sponsorNew":"Leo Pharma \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Innovates Health Solutions | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Innovates Health Solutions | Canadian Institutes of Health Research","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ Alberta Innovates Health Solutions | Canadian Institutes of Health Research"}]

    Find Clinical Drug Pipeline Developments & Deals for ALFACALCIDOL [WHO-DD]

    Menu

    ALFACALCIDOL [WHO-DD]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leo Pharma

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Leo Pharma

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alfacalcidol

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Cheplapharm Arzneimittel Gmbh

                            Deal Size : $355.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Leo Pharma Sells Portfolio of Four Products to Cheplapharm

                            Details : The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.

                            Product Name : One-Alpha

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            August 31, 2020

                            Lead Product(s) : Alfacalcidol

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Cheplapharm Arzneimittel Gmbh

                            Deal Size : $355.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Calgary

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Calgary

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alfacalcidol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Alberta Innovates Health Solutions | Canadian Institutes of Health Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vitamin D and Cardiac Autonomic Tone in Hemodialysis

                            Details : Alfacalcidol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 24, 2013

                            Lead Product(s) : Alfacalcidol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Alberta Innovates Health Solutions | Canadian Institutes of Health Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth